TherapeuticsMD, Inc. (TXMD) financial statements (2021 and earlier)

Company profile

Business Address 951 YAMATO ROAD, SUITE 220
BOCA RATON, FL 33431
State of Incorp. NV
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments80 16212713265
Cash and cash equivalents80 16212713265
Receivables32 11453
Inventory, net of allowances, customer advances and progress billings8 3111
Inventory8 3111
Prepaid expense6 4111
Other undisclosed current assets1 7511
Total current assets:128 18714013971
Noncurrent Assets
Property, plant and equipment2 0   
Intangible assets, net (including goodwill)  4322
Intangible assets, net (excluding goodwill)  4322
Prepaid expense     1
Deposits noncurrent assets  0000
Other noncurrent assets51     
Other undisclosed noncurrent assets  20   
Total noncurrent assets:53 25333
Other undisclosed assets  0010
TOTAL ASSETS:182 21214314274
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities21 3411136
Accounts payable21 23473
Accrued liabilities  3110
Employee-related liabilities  8543
Other liabilities38 18988
Other undisclosed current liabilities  (11)(7)(5)(3)
Total current liabilities:59 41131511
Noncurrent Liabilities
Long-term debt and lease obligation246 73   
Long-term debt, excluding current maturities238 73   
Operating lease, liability9 
Other undisclosed noncurrent liabilities(9)     
Total noncurrent liabilities:246 73   
Total liabilities:306 114131511
Stockholders' equity
Stockholders' equity attributable to parent(124) 9813012763
Common stock0 0000
Additional paid in capital755 617516437283
Accumulated deficit(879) (519)(387)(310)(220)
Total stockholders' equity:(124) 9813012763
TOTAL LIABILITIES AND EQUITY:182 21214314274

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues65 16171920
Revenue, net171920
Cost of revenue
(Cost of Goods and Services Sold)
(16) (3)(3)(4)(5)
Gross profit:49 13141516
Operating expenses(204) (144)(92)(105)(101)
Operating loss:(156) (130)(78)(90)(85)
Nonoperating income (expense)(28) (2)100
Investment income, nonoperating   000
Other nonoperating income1 2100
Interest and debt expense(0) (0)   
Loss from continuing operations before equity method investments, income taxes:(184) (133)(77)(90)(85)
Other undisclosed income from continuing operations before income taxes0 0   
Net loss available to common stockholders, diluted:(184) (133)(77)(90)(85)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(184) (133)(77)(90)(85)
Comprehensive loss, net of tax, attributable to parent:(184) (133)(77)(90)(85)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: